Cargando…

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Akahira, J-i, Aoki, M, Suzuki, T, Moriya, T, Niikura, H, Ito, K, Inoue, S, Okamura, K, Sasano, H, Yaegashi, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409481/
https://www.ncbi.nlm.nih.gov/pubmed/15164121
http://dx.doi.org/10.1038/sj.bjc.6601832
_version_ 1782155775394709504
author Akahira, J-i
Aoki, M
Suzuki, T
Moriya, T
Niikura, H
Ito, K
Inoue, S
Okamura, K
Sasano, H
Yaegashi, N
author_facet Akahira, J-i
Aoki, M
Suzuki, T
Moriya, T
Niikura, H
Ito, K
Inoue, S
Okamura, K
Sasano, H
Yaegashi, N
author_sort Akahira, J-i
collection PubMed
description Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription–polymerase chain reaction (RT–PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERα. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERα were evaluated by RT–PCR in 22 cases. The expression for EBAG9 and ERα was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P=0.0402) and advanced disease (P=0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P=0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (P<0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERα mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERα expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.
format Text
id pubmed-2409481
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24094812009-09-10 Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer Akahira, J-i Aoki, M Suzuki, T Moriya, T Niikura, H Ito, K Inoue, S Okamura, K Sasano, H Yaegashi, N Br J Cancer Molecular and Cellular Pathology Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription–polymerase chain reaction (RT–PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERα. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERα were evaluated by RT–PCR in 22 cases. The expression for EBAG9 and ERα was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P=0.0402) and advanced disease (P=0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P=0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (P<0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERα mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERα expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer. Nature Publishing Group 2004-06-01 2004-05-26 /pmc/articles/PMC2409481/ /pubmed/15164121 http://dx.doi.org/10.1038/sj.bjc.6601832 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Akahira, J-i
Aoki, M
Suzuki, T
Moriya, T
Niikura, H
Ito, K
Inoue, S
Okamura, K
Sasano, H
Yaegashi, N
Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title_full Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title_fullStr Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title_full_unstemmed Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title_short Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer
title_sort expression of ebag9/rcas1 is associated with advanced disease in human epithelial ovarian cancer
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409481/
https://www.ncbi.nlm.nih.gov/pubmed/15164121
http://dx.doi.org/10.1038/sj.bjc.6601832
work_keys_str_mv AT akahiraji expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT aokim expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT suzukit expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT moriyat expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT niikurah expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT itok expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT inoues expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT okamurak expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT sasanoh expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer
AT yaegashin expressionofebag9rcas1isassociatedwithadvanceddiseaseinhumanepithelialovariancancer